The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience

@inproceedings{Doshi2012TheIT,
  title={The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience},
  author={Peter Doshi and Tom Jefferson and Chris Del Mar},
  booktitle={PLoS medicine},
  year={2012}
}
Regulatory approval of new drugs is assumed to reflect a judgment that a medication's benefits outweigh its harms. Despite this, controversy over approved drugs is common. If sales can be considered a proxy for utility, the controversies surrounding even the most successful drugs (such as blockbuster drugs) seem all the more paradoxical, and have revealed the extent to which the success of many drugs has been driven by sophisticated marketing rather than verifiable evidence [1,2]. But even… CONTINUE READING

3 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Consider the case of the influenza antiviral Tamiflu ( oseltamivir ) .
Consider the case of the influenza antiviral Tamiflu ( oseltamivir ) .
OseltamivirHas tradenameTamiflu
Consider the case of the influenza antiviral Tamiflu ( oseltamivir ) .
Consider the case of the influenza antiviral Tamiflu ( oseltamivir ) .
Consider the case of the influenza antiviral Tamiflu ( oseltamivir ) .
All Topics